Larimar Therapeutics Inc. reported that, as of June 30, 2025, the company had approximately $138.5 million in cash, cash equivalents, and marketable securities. This preliminary figure has not been audited, and the final results may vary once the financial statement closing procedures are completed. No specific figures regarding sales, revenues, net income, or profit/loss were disclosed in this update.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.